PRESS RELEASE

MaxiVAX appoints Antonio Perez MD as Chief Medical Officer

- Management team strengthened as MaxiVAX develops ground-breaking Immuno-Oncology therapies
- Company winner of 2017 CTI Swiss Medtech Award

Geneva, Switzerland – 14 December, 2017 – MaxiVAX SA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, today announces the appointment of Antonio Perez MD Ph.D., as its Chief Medical Officer. He joins the company after holding senior medical positions at Novartis, Biogen Idec, Basilea, Almirall and Esteve. He has also been a medical advisor to many companies across Europe and the US.

Dimitrios Goundis, Chief Executive Officer, commented: “We are delighted that Antonio has joined us as Chief Medical Officer. He has a very strong track record in biotech and pharma with expertise in oncology, drug development processes, and an understanding of regulatory agencies in key markets. As MaxiVAX is now in full-fledged clinical development, his experience and strength will benefit us immensely in designing and running trials for various cancer types. Based on game-changing technologies, MaxiVAX is attracting recognition and interest from the cancer and life science communities.”

Antonio Perez, Chief Medical Officer, said: “It is a privilege to be given this opportunity to join MaxiVAX, which is backed by well-known figures in the industry. Cancer immunotherapy is one of the most dynamic therapeutic areas, targeted by many research institutes and life science companies. MaxiVAX has the potential to make a significant contribution to changing the standard of cancer care. I am excited by the company’s novel approach and the promising results to date.”

MaxiVAX received the 2017 CTI Swiss Medtech Award on 13 June 2017 from Swiss Federal Councillor Johann N. Schneider-Amman. This recognised the work done by both MaxiVAX and Prof. Nicolas Mach of Geneva University Hospitals, who is the company’s Chief Scientific Officer. The company’s novel Immuno-Oncology therapeutic vaccination MVX-ONCO-1 was selected live as the winning project by about 600 representatives of the sector who attended Swiss Medtech Day.

The company has successfully completed a phase I trial with MVX-ONCO-1 in 25 patients with a range of cancer types at an advanced stage, when no serious adverse events were reported in the study drug. The product is now in phase II development.
Antonio Perez, MD Ph.D.
Dr Perez has 30 years of experience in the life science sector in research, drug development, registration and launching of therapies in several disease areas. He has held medical positions in oncology at Biogen Idec, Ability Pharma, Elan and Laboratorios Almirall amongst others. He has also consulted as a medical advisor with several companies in key markets across Europe and the US. Earlier in his career, he held roles in clinical research in anti-infectives at Basilea and Novartis. He has been an author in over 40 publications. Antonio was awarded his PhD and graduated in medicine from the Universitat Autònoma de Barcelona, Spain, before practicing as a specialist in Intensive Care Medicine at various hospitals in Spain.

About MVX-ONCO-1
MaxiVAX’s novel Immuno-Oncology therapeutic vaccination is based on triggering the patient’s own natural immune response mechanism via an innovative and proprietary technology in order to eliminate cancer cells. MVX-ONCO-1 has been classified as an Advanced Therapeutic Medicinal Product by the European Medicines Agency (EMA).

MVX-ONCO-1 is a product that contains two distinct biological entities:

1) **Vaccine**: administered by sub-cutaneous injection, using the patient’s own irradiated cancer cells as vaccine antigens, with a key benefit of using the entire set of tumor antigens from the patient’s own cells.

2) **Immune boosting agent**: an immune boosting agent (GM-CSF: granulocyte macrophage- colony stimulating factor) is delivered at the site of vaccination in a sustained manner, via genetically reprogrammed cells, encapsulated in a small biocompatible capsule. Two capsules, which are essential to protect the GM-CSF producing cells, are placed underneath the skin at the same site as the vaccine injection. After 1 week the capsules are removed.

The treatment is repeated for a total of 6 immunizations over a period of 8 weeks.

This innovative technology of protein delivery by encapsulated cells was pioneered by Prof. P. Aebischer, former President of EPFL in Lausanne, who has been an advisor to MaxiVAX since its foundation.

About MaxiVAX  [www.maxivax.ch](http://www.maxivax.ch)
MaxiVAX is a private Swiss clinical-stage biotech company with a novel, patient-specific and personalized active immunotherapy treatment for cancer. The company received the 2017 CTI Swiss Medtech Award for its ground-breaking approach.

Its lead product MVX-ONCO-1 combines a vaccination process against the complete tumor cell with an immune system-boosting agent, provided in a sustained manner. This unique combination triggers a protective immune response against multiple cancer types. MVX-ONCO-1 has completed a phase I trial in patients suffering from various solid cancers at an advanced stage. This trial confirmed a benign safety profile with encouraging efficacy data, and the product is now in phase II development.
Investor and Business Development Contact
Dimitrios Goundis Ph.D.
CEO
dgoundis@maxivax.ch
+41 22 552 26 13
MaxiVAX SA
Rue de l’Athénée 24
CH-1206 Geneva
Switzerland

Media Contact
Nick Miles / Toomas Kull
Cabinet Privé de Conseils s.a.
Genève, Suisse
Téléphone : +41 22 552 46 46
Mobile : +41 79 678 76 26
E-mail : miles@cpc-pr.com
        kull@cpc-pr.com

Edward Agne
The Communications Strategy Group Inc.
Cambridge, Massachusetts, États-Unis
Téléphone : +1 781 631 3117
Mobile : +1 781 888 0099
E-mail : edagne@com stratgroup.com